Erratum

Erratum to “Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials”

Mark A. Fletcher and Bernard Fritzell

Pfizer Specialty Care Business Unit-Vaccines, International Scientific & Clinical Affairs, Pfizer Inc, 75668 Paris Cedex 14, France

Correspondence should be addressed to Mark A. Fletcher, mark.a.fletcher@pfizer.com

Received 27 July 2012; Accepted 9 August 2012

Copyright © 2012 M. A. Fletcher and B. Fritzell. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Subsequent to the publication of the previous paper entitled “Pneumococcal Conjugate Vaccines and Otitis Media: An Appraisal of the Clinical Trials,” scientific errors were discovered in Table 4. Therefore, an erratum was submitted with corrections to the table.
Table 4: Vaccine efficacy values in the long-term followup of PCV clinical trials with otitis media as an endpoint [3, 13]. Adapted with permission from Fletcher and Fritzell, 2007 Elsevier Ltd. All rights reserved [7].

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Study vaccine</td>
<td>PCV7-CRM</td>
<td>PCV7-CRM</td>
</tr>
<tr>
<td>Number</td>
<td>27,754</td>
<td>756</td>
</tr>
<tr>
<td>Age</td>
<td>Until aged 3.5 years</td>
<td>Until aged 4-5 years</td>
</tr>
</tbody>
</table>

Clinical endpoints*: vaccine efficacy, % (95% CI)

- **Otitis media visits (NCKP) or episodes (FinOM)**
  - **PP**: 8 (5–11) 8 (–2 to 16)
  - **ITT**: 7 (5–9) —

- **Recurrent otitis media**
  - **3/4**: 10 (7–13) 18 (1–32); 50 (15–71)
  - **5/6**: — —
  - **≥10†**: 26 (12–38) —

- **All tympanostomy-tube placements**
  - 23 (–10 to 46) 39 (4–61); 49 (–7 to 76)

- **Rate of AOM-related ambulatory visits**
  - 8 (5–10) —

- **Rate of antibiotic prescriptions for AOM**
  - 6 (4–7) —

* See Table 1 for primary otitis media endpoint, otitis media definition, myringotomy criteria, and source of MEF in each study.
** Number of episodes in 6 months/number of episodes in 1 year.
† Efficacy against 10 or more episodes within 6 months.
§ Primary analysis set (see Section 3.5.2. FinOM vaccine trial).
¶ Secondary analysis set (see Section 3.5.2. FinOM vaccine trial).
Reported values are rounded to whole numbers; dash line indicates not reported.
Cl: confidence interval; ITT: intent to treat; PP: per-protocol.
Submit your manuscripts at
http://www.hindawi.com